FDA to reconsider Braeburn’s opioid addiction drug after court ruling

A US district court has ruled that the FDA must reconsider its decision to reject a long-lasting opioid addiction treatment drug from Braeburn, overthrowing a ruling granting exclusivity to an established rival from Indivior.